Comparison of efficacy and safety of ripertamab (SCT400) versus rituximab (Mabthera®) in combination with CHOP in patients with previously untreated CD20‐positive diffuse large B‐cell lymphoma: A randomized, single‐blind, phase III clinical trial
Sign Up to like & getrecommendations! Published in 2022 at "Hematological Oncology"
DOI: 10.1002/hon.3054
Abstract: This study compared the efficacy, safety and immunogenicity of ripertamab (SCT400) and rituximab (Mabthera®) combined with CHOP as the first‐line treatment for Chinese patients with CD20‐positive diffuse large B cell lymphoma (DLBCL). This is a… read more here.
Keywords: cd20 positive; safety; chop; rituximab mabthera ... See more keywords
A Method for the Elution of Anti-CD20 With an EDTA/Glycine Acid Solution for Accurate Immunophenotyping of B Lymphocytes Sensitized With Rituximab.
Sign Up to like & getrecommendations! Published in 2021 at "American journal of clinical pathology"
DOI: 10.1093/ajcp/aqab176
Abstract: OBJECTIVES To assess the efficacy of a method to circumvent CD20-positive antigen masking by rituximab for flow cytometry analysis of B-cell malignancies in hematology patients. METHODS Mononuclear cells (MNCs) from 10 healthy individuals and 5… read more here.
Keywords: elution; sensitized rituximab; cd20 positive; method ... See more keywords
Prognostic variables and 4-year survival outcomes in CD20 Positive AIDS-Related Lymphoma in the Anti-retroviral treatment era: A Retrospective Review from a Single Centre in KwaZulu-Natal, South Africa
Sign Up to like & getrecommendations! Published in 2022 at "PLoS ONE"
DOI: 10.1371/journal.pone.0272282
Abstract: Objective To describe 4-year survival outcomes and assess the value of established and additional relevant variables to predict complete response (CR), four-year progression-free survival (PFS) and overall survival (OS) of CD20 positive AIDS-Related Lymphoma (ARL)… read more here.
Keywords: year survival; cd20 positive; year; positive aids ... See more keywords
CD20 expression sub-stratifies standard-risk patients with B cell precursor acute lymphoblastic leukemia
Sign Up to like & getrecommendations! Published in 2017 at "Oncotarget"
DOI: 10.18632/oncotarget.22207
Abstract: Patients with standard-risk adult acute lymphoblastic leukemia (ALL) treated with chemotherapy do not have satisfactory outcomes. To more precisely classify ALL patients and optimize treatment, we re-evaluated the risk stratification system by examining CD20 expression… read more here.
Keywords: risk; cd20 positive; standard risk; cd20 negative ... See more keywords